Sachdev Deepali, Yee Douglas
University of Minnesota Cancer Center, MMC 806, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA.
Mol Cancer Ther. 2007 Jan;6(1):1-12. doi: 10.1158/1535-7163.MCT-06-0080.
The type I insulin-like growth factor receptor (IGF-IR) plays multiple roles in several cancers and increased circulating levels of insulin-like growth factor-I (IGF-I) are associated with increased risk of breast, colon, and prostate cancers. Because IGF-II and insulin signal via the insulin receptor (IR) to stimulate the growth of cancer cells, inhibition of IR might be necessary to totally disrupt the action of IGFs and their receptors. This review describes the well-recognized roles of IGF-IR in driving the malignant phenotype, examines the evidence that perhaps IR should also be targeted to inhibit the effects of the IGF ligands and insulin in cancer, describes the strategies to disrupt IGF signaling in cancer, and highlights some key issues that need to be considered as clinical trials targeting IGF-IR proceed.
I型胰岛素样生长因子受体（IGF-IR）在多种癌症中发挥多种作用，而循环中胰岛素样生长因子-I（IGF-I）水平升高与乳腺癌、结肠癌和前列腺癌风险增加相关。由于IGF-II和胰岛素通过胰岛素受体（IR）发出信号以刺激癌细胞生长，抑制IR可能对于完全阻断IGF及其受体的作用是必要的。本综述描述了IGF-IR在驱动恶性表型方面公认的作用，审视了或许也应靶向IR以抑制IGF配体和胰岛素在癌症中作用的证据，描述了在癌症中阻断IGF信号传导的策略，并强调了在针对IGF-IR的临床试验推进过程中需要考虑的一些关键问题。
